Antibody Drug Conjugates

Through WuXi XDC, a subsidiary of WuXi Biologics, we offer global clients a comprehensive ADC/bioconjugate drug CRDMO service platform. Covering discovery, preclinical activities, CMC development, and the complete manufacturing supply chain, WuXi XDC delivers an all-in-one solution within a single company and in one centralized region. Not only does WuXi XDC provide a single-source solution for the bioconjugate drug substance and drug product, but it also offers the entire value chain from discovery to commercial-scale GMP manufacturing for key intermediates (i.e., small molecule payload linkers and biologics).   

In addition, all activities and services performed at WuXi XDC are conducted within 1-2 hours (driving), thus providing an unprecedented geographic advantage. On top of these extensive capabilities, the services for ADC / bioconjugate products are expanding globally over the next few years with R&D capabilities in the U.S. and the creation of a global dual source manufacturing network through the new facilities established in Singapore.